Labcorp Holdings Inc.
Every calculator, already run for LH
Open the full toolkit →You have the numbers on LH. Get the argument.
A written report on which of these readings actually decide the outcome for Labcorp Holdings Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
18 analysts covering LHAnalyst Price Target Disagreement for Labcorp Holdings Inc.
Wall Street's bull case implies +15% from the current price; the bear case implies -13%. Analysts are relatively aligned on LH's range.
Ownership & short interest
Insider Trading Activity for LH
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, wome…
LH — frequently asked
Is LH a buy right now?
Wall Street's consensus rating on Labcorp Holdings Inc. is Buy across 18 analysts, with a mean price target of $341.50 (+2% vs. the current $335.10). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LH overvalued?
LH trades at 27.7x trailing earnings, against a DCF fair value of $290 per share. The current price implies 8% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LH's next earnings date?
Labcorp Holdings Inc. is next scheduled to report earnings around Nov 3, 2026. A full LH research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Labcorp Holdings Inc.?
Analysts covering Labcorp Holdings Inc. (LH) range from a bear-case target of $293.00 to a bull-case high of $385.00, with a mean consensus target of $341.50 across 16 analysts. The spread of $92.00 (27% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Labcorp Holdings Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Labcorp Holdings Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LH research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Labcorp Holdings Inc., in minutes. 3 free reports included with every account — no credit card required.